GS010 event:
GenSight Biologics to Host KOL Event on June 12, 2018 in New York City
Our products and pipeline
Our technologies
News & Media
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)
GENSIGHT BIOLOGICS S.A.
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
+33 1 76 21 72 20
infos@gensight-biologics.com
Contact us
GENSIGHT BIOLOGICS Inc.
3 East 28th Street
New York, NY 10016
USA
3 East 28th Street
New York, NY 10016
USA
nyc@gensight-biologics.com
Contact us